One-component nanomedicine

被引:126
作者
Su, Hao [1 ,2 ]
Koo, Jin Mo [1 ]
Cui, Honggang [1 ,2 ,3 ,4 ,5 ]
机构
[1] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA
[2] Johns Hopkins Univ, Inst NanoBioTechnol, Baltimore, MD 21218 USA
[3] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[4] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA
[5] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Ctr Nanomed, Baltimore, MD 21231 USA
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
Nanomedicine; Drug delivery; BLOCK-COPOLYMER MICELLES; DOXORUBICIN-CONJUGATE NANOPARTICLES; LINKED POLYMER NANOPARTICLES; RING-OPENING POLYMERIZATION; ELASTIN-LIKE POLYPEPTIDE; DRUG-DELIVERY; SUPRAMOLECULAR HYDROGELS; CONTROLLED-RELEASE; CANCER-THERAPY; MAGNETIC NANOPARTICLES;
D O I
10.1016/j.jconrel.2015.09.056
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
One-component nanomedicine (OCN) represents an emerging class of therapeutic nanostructures that contain only one type of chemical substance. This one-component feature allows for fine-tuning and optimization of the drug loading and physicochemical properties of nanomedicine in a precise manner through molecular engineering of the underlying building blocks. Using a precipitation procedure or effective molecular assembly strategies, molecularly crafted therapeutic agents (e.g. polymer-drug conjugates, small molecule prodrugs, or drug amphiphiles) could involuntarily aggregate, or self-assemble into nanoscale objects of well-defined sizes and shapes. Unlike traditional carrier-based nanomedicines that are inherently multicomponent systems, an OCN does not require the use of additional carriers and could itself possess desired physicochemical features for preferential accumulation at target sites. We review here recent progress in the molecular design, conjugation methods, and fabrication strategies of OCN, and analyze the opportunities that this emerging platform could open for the new and improved treatment of devastating diseases such as cancer. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:383 / 395
页数:13
相关论文
共 191 条
[1]  
ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3578
[2]   Site-Specific Antibody-Drug Conjugates: The Nexus of Biciorthogonal Chemistry, Protein Engineering, and Drug Development [J].
Agarwal, Paresh ;
Bertozzi, Carolyn R. .
BIOCONJUGATE CHEMISTRY, 2015, 26 (02) :176-192
[3]   Functional Supramolecular Polymers [J].
Aida, T. ;
Meijer, E. W. ;
Stupp, S. I. .
SCIENCE, 2012, 335 (6070) :813-817
[4]   FDA-approved poly(ethylene glycol)-protein conjugate drugs [J].
Alconcel, Steevens N. S. ;
Baas, Arnold S. ;
Maynard, Heather D. .
POLYMER CHEMISTRY, 2011, 2 (07) :1442-1448
[5]   A Hybrid Protein - Polymer Nanoworm Potentiates Apoptosis Better than a Monoclonal Antibody [J].
Aluri, Suhaas Rayudu ;
Shi, Pu ;
Gustafson, Joshua A. ;
Wang, Wan ;
Lin, Yi-An ;
Cui, Honggang ;
Liu, Shuanglong ;
Conti, Peter S. ;
Li, Zibo ;
Hu, Peisheng ;
Epstein, Alan L. ;
MacKay, John Andrew .
ACS NANO, 2014, 8 (03) :2064-2076
[6]   Supramolecular polymeric hydrogels [J].
Appel, Eric A. ;
del Barrio, Jesus ;
Loh, Xian Jun ;
Scherman, Oren A. .
CHEMICAL SOCIETY REVIEWS, 2012, 41 (18) :6195-6214
[7]   Squalene Based Nanocomposites: A New Platform for the Design of Multifunctional Pharmaceutical Theragnostics [J].
Arias, Jose L. ;
Reddy, L. Harivardhan ;
Othman, Mohammad ;
Gillet, Brigitte ;
Desmaele, Didier ;
Zouhiri, Fatima ;
Dosio, Franco ;
Gref, Ruxandra ;
Couvreur, Patrick .
ACS NANO, 2011, 5 (02) :1513-1521
[8]   Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: Tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy [J].
Bae, Y ;
Nishiyama, N ;
Fukushima, S ;
Koyama, H ;
Yasuhiro, M ;
Kataoka, K .
BIOCONJUGATE CHEMISTRY, 2005, 16 (01) :122-130
[9]   Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method [J].
Barichello, JM ;
Morishita, M ;
Takayama, K ;
Nagai, T .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1999, 25 (04) :471-476
[10]   Strategies and challenges for the next generation of therapeutic antibodies [J].
Beck, Alain ;
Wurch, Thierry ;
Bailly, Christian ;
Corvaia, Nathalie .
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (05) :345-352